What do systematic reviews say?

Inhaled corticosteroids vs no treatment or placebo

• Postnatal corticosteroids for transient tachypnoea of the newborn 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Very low

Inhaled corticosteroids plus standard care vs placebo or usual care

Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).

• Inhaled corticosteroids for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
  RR 1.19 [1.09, 1.3]
  2 studies · 1986 participants
  Moderate

Inhaled corticosteroids vs placebo

It is very uncertain whether summary of findings: inhaled corticosteroids changes respiratory exacerbations: number of days on intravenous antibiotics… compared with placebo (very low certainty).

• Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Inhaled corticosteroids vs placebo

It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).

• Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
  RR 1.1 [0.74, 1.63]
  1 study · 30 participants
  Very low

Inhaled corticosteroids vs placebo

It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).

• Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
  RR 3 [0.35, 25.78]
  3 studies · 61 participants
  Very low

Inhaled corticosteroids vs placebo

It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).

• Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
  RR 1 [0.59, 1.7]
  1 study · 30 participants
  Very low

Inhaled corticosteroids vs placebo

It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).

• Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
  RR 0.51 [0.26, 1]
  4 studies · 74 participants
  Very low